Overview
Surgery Partners Q3 revenue up 6.6% but slightly missed analyst expectations
Adjusted EPS for Q3 missed analyst estimates
Adjusted EBITDA rose 6.1% to $136.4 mln, slightly below estimates
Outlook
Company revises full-year guidance due to softer volume and payor mix trends
Company expects full-year revenue between $3.275 bln and $3.30 bln
Company anticipates full-year Adjusted EBITDA between $535 mln and $540 mln
Result Drivers
ORTHOPEDIC PROCEDURES - Co cites strength in orthopedic procedures as a key driver of topline growth
VOLUME AND PAYOR MIX - Co notes softer volume and payor mix trends impacted performance
M&A PIPELINE - Co continues to evaluate M&A pipeline and portfolio optimization opportunities
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Slight Miss*
$821.50 mln
$822 mln (10 Analysts)
Q3 Adjusted EPS
Miss
$0.13
$0.17 (11 Analysts)
Q3 Adjusted EBITDA
Slight Miss*
$136.40 mln
$137.30 mln (10 Analysts)
Q3 Adjusted EBITDA Margin
16.60%
Q3 Operating Income
$105.70 mln
Q3 Pretax Profit
$30.80 mln
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Surgery Partners Inc is $32.00, about 32.8% above its November 7 closing price of $21.50
The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 22 three months ago
Press Release: ID:nGNX8zsHfd
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)